Growth Guidance

Showing 2591 articles
Business

Enova International Posts Strong 2025 Results Fueled by Lending Growth and Buybacks, But High Leverage Raises Questions

Enova International reports robust revenue and earnings growth for Q4 and full-year 2025, driven by expansion in its consumer and small business lending segments and a significant share repurchase program. While the financial technology lender's machine-learning underwriting and capital returns strategy have rewarded shareholders, analysts point to its elevated debt load and exposure to economic cycles as key areas for investor scrutiny.

Business

Adtalem Bets Big on Buybacks: A Strategic Pivot in Healthcare Education?

Adtalem Global Education posts strong Q2 fiscal 2026 results, raising revenue to $503.39M and net income to $76.38M, while reaffirming full-year guidance. The company's new $750M share repurchase authorization signals a dual commitment to capital returns and strategic growth in its healthcare education portfolio, even as regulatory and enrollment challenges linger.

Business

DaVita Navigates Headwinds as Integrated Kidney Care Turns Profitable Ahead of Schedule

DaVita Inc. reported Q4 2025 results in line with expectations, highlighting a milestone first profitable year for its Integrated Kidney Care unit. While revenue per treatment accelerated, the company continues to face pressure from elevated patient mortality and rising benefit costs. Executives provided 2026 guidance projecting mid-single-digit operating income growth and a sharp rise in EPS, buoyed by share buybacks and the stabilization of prior investment losses.